NuVasive Inc. Third Quarter Earnings Sneak Peek

NuVasive, Inc. (NASDAQ:NUVA) will unveil its latest earnings on Thursday, October 27, 2011. NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders.

NuVasive, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 13 cents per share, a decline of 55.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 20 cents. Between one and three months ago, the average estimate moved down. It also has dropped from 14 cents during the last month. For the year, analysts are projecting profit of 61 cents per share, a decline of 33.7% from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 2 cents, reporting net income of 19 cents per share against a mean estimate of profit of 17 cents per share.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 11.6% in revenue from the year-earlier quarter to $134.2 million.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, none rating it as a sell and nine rating it as a hold. Over the past 90 days, the average rating for the stock has moved up from hold to moderate buy.

A Look Back: In the second quarter, profit fell 20% to $5.4 million (13 cents a share) from $6.7 million (17 cents a share) the year earlier, but exceeded analyst expectations. Revenue rose 11.2% to $133 million from $119.6 million.

Key Stats:

The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that span, the company has averaged growth of 18.2%, with the biggest boost coming in the third quarter of the last fiscal year when revenue rose 26.7% from the year earlier quarter.

The decrease in profit in the second quarter broke a streak of three consecutive quarters of year-over-year profit increases. Net income rose more than twofold in the first quarter, 2615.1% in the fourth quarter of the last fiscal year and 68.7% in the third quarter of the last fiscal year.

Competitors to Watch: Alphatec Holdings, Inc. (NASDAQ:ATEC), Stryker Corporation (NYSE:SYK), Zimmer Holdings, Inc. (NYSE:ZMH), TranS1 Inc. (NASDAQ:TSON), Orthofix International NV (NASDAQ:OFIX), Medtronic, Inc. (NYSE:MDT), Exactech, Inc. (NASDAQ:EXAC), Wright Medical Group, Inc. (NASDAQ:WMGI), Orthovita, Inc. (NASDAQ:VITA), and RTI Biologics Inc. (NASDAQ:RTIX).

Stock Price Performance: During July 28, 2011 to October 21, 2011, the stock price had fallen $11.91 (-40.7%) from $29.24 to $17.33. The stock price saw one of its best stretches over the last year between April 8, 2011 and April 18, 2011 when shares rose for seven-straight days, rising 7.3% (+$1.87) over that span. It saw one of its worst periods between July 28, 2011 and August 8, 2011 when shares fell for eight-straight days, falling 22.1% (-$6.46) over that span. Shares are down $8.32 (-32.4%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.